A Rare Cancer, A Powerful Tool: What the New Guidelines Mean for Merkel Cell Carcinoma Patients
Read Article
Oncology
Resources related to tests that help detect circulating tumor DNA for molecular residual disease assessment.
-
-
How MRD Testing Supports Colorectal Cancer Patients: Jason’s Story and the Importance of Regular Monitoring
Read Article
-
Jason's Patient Testimonial
Watch Video
-
MRD Testing in NSCLC to Personalize Patient Care
Watch Video
-
Unlocking new uses for old drugs
a revolution in precision oncology using evidence-based MRD testing
Watch Video
-
Medicare Expands Coverage of Signatera for Patients with Lung Cancer
Read Article
-
How to Use Natera’s Patient Portal to Manage Your Cancer Care
Read Article
-
What Is MRD Testing and How Can It Help Monitor Cancer Recurrence?
Read Article
-
Capture More Patients & Families Who Can Benefit from Hereditary Cancer Testing
Utilizing the Natera Hereditary Cancer Alert Program and Oncologist Initiated Testing
Watch Video
-
New data: Optimizing breast cancer care and drug development with molecular residual disease testing
Watch Video
-
Signatera for Colorectal Liver Metastases
Read More
-
Natera at SABCS 2024: What It Means for Breast Cancer Survivors
Read Article
-
How to Talk to Your Doctor About Signatera for Lung Cancer
Learn how to talk to your doctor about Signatera for lung cancer recurrence monitoring. Understand the benefits of ctDNA testing, how it detects recurrence early, and why it’s vital for personalized c
Read Article
-
The Tipping Point: How clinically validated MRD testing is transforming patient management in colorectal cancer
Watch Video
-
Utilization of Circulating Tumor DNA in the Surveillance Setting
Gibbs JN, Dale PS, Weatherall AL. The American Surgeon. 2023
Read More
-
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumors
Kalashnikova E, Aushev, VA, Malashevich AK, et al. Molecular Oncology. 2023
Read More
-
Immunologic signatures of response and resistance to nivolumab with ipilimumab in advanced metastatic cancer
Tsimberidou AM, Alayli FA, Okrah K, et al. Journal of Experimental Medicine. 2024
Read More
-
Combined Transcriptome and Circulating Tumor DNA Longitudinal Biomarker Analysis Associates With Clinical Outcomes in Advanced Solid Tumors
Hernando-Calvo A, Yang SYC, Vila-Casadesús M, et al. JCO Precis Oncol. 2024
Read More
-
Tumor-informed ctDNA assessment as a valuable prognostic and predictive biomarker in diffuse large B-cell lymphoma
Narkhede M, Tomassetti S, Iqbal M. Front. in Oncol 2024
Read More
-
Efficacy of PARP inhibitor therapy after targeted BRAF/MEK failure in advanced melanoma
Phillipps J, Nassief G, Morecroft R, et al. NPJ Precision Oncology. 2024
Read More
-
Loading More...
